Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays

Urology

Volumn 55, Issue 6, 2000, Pages 909-914

  Vessella, Robert L ^e   Lange, Paul H ^a   Partin, Alan W ^b   Chan, Daniel W ^b   Sokoll, Lori J ^b   Sasse, Edward A ^c   Crawford, E David ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c CLEMENT J ZABLOCKI VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; STATISTICS;

BIOPSY; HUMANS; IMMUNOASSAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 0034105104     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(00)00461-1     Document Type: Article

References (22)

1. Christensson A., Laurell C.-B., Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem. 194:1990;755-763.
2. Lilja H., Christensson A., Dahlen U., et al. Prostate specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
3. Christensson A., Björk T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 150:1993;100-105.
4. Vashi A.R., Wojno K.J., Henricks W., et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology. 49:1997;19-27.
5. Catalona W.J., Smith D.S., Wolfert R.L., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 274:1995;1214-1220.
6. Chen Y.-T., Luderer A.A., Thiel R.P., et al. Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology. 47:1996;518-524.
7. Partin AW, and Oesterling JE (Eds): The Clinical Usefulness of Percent Free Prostate-Specific Antigen (Special Issue). Urology 48(suppl 6A): 1996.
8. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA. 279:1998;1542-1547.
9. Woodrum D.L., Brawer M.K., Partin A.W., et al. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol. 159:1998;5-12.
10. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., et al. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA) two closely related, but distinct, kallikreins in the prostate . Crit Rev Clin Lab Sci. 35:1998;275-368.
11. Dowell B., Friese J., Rapp J., et al. Development of the Abbott AxSYM Free PSA and Total PSA assays performance characteristics and preliminary clinical evaluation . Clin Chem. 42:1996;S265-S705.
12. Woodrum D., York L. Two-year stability of free and total PSA in frozen serum samples. Urology. 52:1998;247-251.
13. TM automated benchtop immunochemistry analyzer system. Clin Chem. 34:1988;1726-1732.
14. Stamey T.A. Some comments on progress in the standardization of immunoassays for prostate-specific antigen. Br J Urol. 79:(suppl 1):1997;49-52.
15. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves a nonparametric approach . Biometrics. 44:1988;837-846.
16. Agresti A. Analysis of Ordinal Categorical Data. 1984;John Wiley & Sons, New York.
17. Gion M., Mione R., Barioli P., et al. Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions. Clin Chem. 44:1998;2462-2470.
18. Marley G.M., Miller M.C., Kattan M.W., et al. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology. 48:(suppl 6A):1996;16-22.
19. Veltri R.W., Miller M.C. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate critical analysis of two different test populations . Urology. 53:1999;736-745.
20. Carlson G.D., Calvanese C.B., Partin A.W. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer results on 4298 cases . Urology. 52:1998;455-461.
21. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter clinical trial . JAMA. 279:1998;1542-1547.
22. Littrup P.J., Goodman A.C. Economic considerations of prostate cancer the role of detection specificity and biopsy reduction . Cancer. 75:(suppl):1995;1987-1993.